Peritoneal malignancies include primary and metastatic cancer of the peritoneal cavity. The most common origin for peritoneal metastasis is ovarian, gastric, and colorectal cancers. Irrespective of the origin, peritoneal metastases represent the advanced disease and are associated with poor long-term outcomes. The minimally invasive approach of pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows repeated applications and objective assessment of tumor response by comparing histological samples. This study aimed to investigate the initial experience with PIPAC in the Baltic region. All patients who underwent PIPAC at Vilnius University Hospital Santaros Klinikos between 2015 and 2020 were included in this retrospective study. The primary outcome of the study was overall survival (OS) in patients with peritoneal carcinomatosis treated by PIPAC. The secondary outcomes included postoperative morbidity; peritoneal carcinomatosis index (PCI) and ascites reduction after treatment by PIPAC. In total, 15 patients underwent 34 PIPAC procedures. PIPAC-related intraoperative and postoperative morbidity occurred in 3 (8.8%) of 34 procedures. Following PIPAC, the median PCI decreased from 8 (4; 15) to 5 (1; 16) in GC patients, although, the difference failed for significance, p = 0.581. In OC patients, PCI after PIPAC remained stable. Median overall survival after PIPAC procedure was 25 (95% CI 5–44) months. Ovarian cancer patients (22; 95% CI 12–44 months) had significantly higher OS, compared to gastric cancer patients (8; 95% CI 4–16 months), p = 0.018. PIPAC is safe and feasible for patients with gastric and ovarian cancers peritoneal metastases.

中文翻译：

---

腹膜恶性肿瘤加压腹腔内气雾剂化疗 (PIPAC)：波罗的海国家第一个项目的初步经验

腹膜恶性肿瘤包括腹膜腔的原发癌和转移癌。腹膜转移最常见的来源是卵巢癌、胃癌和结直肠癌。无论起源如何，腹膜转移都代表晚期疾病，并且与不良的长期结果相关。加压腹腔内气雾剂化疗 (PIPAC) 的微创方法允许通过比较组织学样本重复应用和客观评估肿瘤反应。本研究旨在调查 PIPAC 在波罗的海地区的初步经验。这项回顾性研究包括了 2015 年至 2020 年在维尔纽斯大学医院 Santaros Klinikos 接受 PIPAC 的所有患者。该研究的主要结果是接受 PIPAC 治疗的腹膜癌病患者的总生存期 (OS)。次要结果包括术后发病率；腹膜癌病指数 (PCI) 和经 PIPAC 治疗后腹水减少。总共有 15 名患者接受了 34 次 PIPAC 手术。34 例手术中有 3 例（8.8%）发生了 PIPAC 相关的术中和术后并发症。在 PIPAC 之后，GC 患者的中位 PCI 从 8 (4; 15) 减少到 5 (1; 16)，尽管差异没有显着性，p = 0.581。在 OC 患者中，PIPAC 后 PCI 保持稳定。PIPAC 手术后的中位总生存期为 25 (95% CI 5–44) 个月。与胃癌患者（8；95% CI 4-16 个月）相比，卵巢癌患者（22；95% CI 12-44 个月）的 OS 显着更高，p = 0.018。